|
| Status |
Public on Mar 09, 2021 |
| Title |
Copy-number profiling by SNP array of 4 acute myeloid leukemia (AML) cell lines |
| Organism |
Homo sapiens |
| Experiment type |
Genome variation profiling by SNP array
|
| Summary |
DNMT inhibitors (DNMTi) are finally approved for AML/MDS, also based on their activity in patients with high-risk cytogenetics (often monosomal karyotype) such as -5/del(5q) or -7/del(7q), often - but not always - harboring TP53-mutations. Several studies provided evidence for aberrant hypermethylation/silencing on monoallelic gene loci, including tumor suppressor genes. We hypothesized that transcriptional repression on monosomal gene loci may be preferentially reversed by DNMTi. Using an unbiased RNA-seq approach we aimed to identify preferentially regulated genes in cells monoallelic for chromosome 7q.
|
| |
|
| Overall design |
Affymetrix SNP arrays were performed according to the manufacturer's protocol on DNA extracted from the cultured AML cell lines UCSD-AML1, ELF-153, KG-1 and U937.
|
| Web link |
https://cancerres.aacrjournals.org/content/81/4/834.long
|
| |
|
| Contributor(s) |
Greve G, Pfeifer D |
| Citation(s) |
33203699 |
| Submission date |
Oct 04, 2019 |
| Last update date |
Mar 11, 2021 |
| Contact name |
Gabriele Greve |
| E-mail(s) |
gabriele.greve@uniklinik-freiburg.de
|
| Organization name |
University of Freiburg Medical Center
|
| Department |
Department of Internal Medicine 1
|
| Lab |
Division of Hematology, Oncology and SCT, Lab Prof. Michael Lübbert
|
| Street address |
Hugstetter Str 55
|
| City |
Freiburg |
| ZIP/Postal code |
79106 |
| Country |
Germany |
| |
|
| Platforms (2) |
| GPL6801 |
[GenomeWideSNP_6] Affymetrix Genome-Wide Human SNP 6.0 Array |
| GPL18637 |
[CytoScan750K_Array] Affymetrix CytoScan 750K Array |
|
| Samples (4)
|
| GSM4107987 |
Acute myeloid leukemia cell line UCSD-AML1 |
| GSM4107988 |
Acute myeloid leukemia cell line ELF-153 |
| GSM4107989 |
Acute myeloid leukemia cell line KG-1 |
|
| Relations |
| BioProject |
PRJNA575864 |
Less...
More...